Abstract:
Provided herein is a method of promoting tissue repair, comprising delivering to a subject a therapeutically effective amount of fibromodulin (FMOD), FMOD polypeptide, FMOD peptide, or a variant or derivative or analog thereof according to a dosing regimen to cause an injured tissue to form a repaired tissue having an improved condition provided that the improved condition does not include improved condition of scar of skin.
Abstract:
The application discloses an implantable device, comprising a galvanic redox system formed on a body substrate of the implantable device. The implantable device has a non-zero surface potential when it is deployed. The galvanic redox system comprises a first metal site and a second metal site, the first metal site comprising a first metal having a first metal electrode potential (FMEP) and the second metal site comprising a second metal having a second metal electrode potential (SMEP), which FMEP being lower than SMEP and SMEP being substantially different such that the implantable device is galvanized when it is deployed. Methods of making and using the implantabe device are also disclosed.
Abstract:
The present invention provides a fibromodulin (FMOD) reprogrammed (FReP) cell and a method of making therefor, a culture medium therefor, and a supernatant thereof, and methods of making and using these.
Abstract:
The present invention discloses methods and compositions for treating or ameliorating a condition associated with increased or decreased myofibroblast activities and use thereof.
Abstract:
The present invention discloses methods and compositions for treating or ameliorating a condition associated with increased or decreased myofibroblast activities and use thereof.
Abstract:
The present invention provides a method of forming a fibromodulin (FMOD) reprogrammed (FReP) cell.This application includes the sequence listing which is identical to the sequence information in the last filed computer readable form (CFR) on Aug. 1, 2014 in U.S. application Ser. No. 14/353,284, filed Apr. 21, 2014, entitled “2014-08-01 384578-991391 ST25.tax” and is hereby incorporated by reference in its entirety.
Abstract:
The present invention provides a method of treating a disorder using a fibromodulin (FMOD) reprogrammed (FReP) cell. The method comprises administering locally to a human being the FReP cell to a site in need thereof of the human being.
Abstract:
The present invention discloses methods and compositions for treating or ameliorating a condition associated with increased or decreased myofibroblast activities and use thereof.
Abstract:
The present invention provides pluripotent stem cell like (PSCL) cells or clones, a culture medium therefore, and a supernatant thereof, and methods of making and using the same.
Abstract:
The present invention provides a fibromodulin (FMOD) reprogrammed (FReP) cell and a method of making therefor, a culture medium therefor, and a supernatant thereof, and methods of making and using these.